Project Grant R01AI197181
Award Date 9/1/26
Completion Date 8/30/30
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $140,496 on January 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of cytochrome BD in supporting flagellar motility in uropathogenic Escherichia coli. The research elucidates connections between bacterial aerobic respiration and flagellar motility in UPEC, the primary cause of urinary tract infections, with the goal of identifying pathways essential...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded Vanderbilt University $100,228.00 on December 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant to investigate how intracellular Pseudomonas aeruginosa exploits host fatty acid metabolism during urinary tract infections. The funded research will identify mechanisms by which P. aeruginosa hijacks host fatty acid...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $153,560 on October 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate subcellular compartmentalization of sulfur metabolism in Acinetobacter baumannii, a bacterial pathogen responsible for 15–25 percent of ventilator-associated pneumonia cases in hospitals. The research examines how A. baumannii regulates sulfur uptake and metabolism during...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $617,438 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid cell-based diagnostic test for urinary tract infections and antimicrobial resistance screening. The project addresses the clinical need for point-of-care UTI diagnosis and antibiotic selection. Current diagnostic methods—urine analysis and culture—require 1–3 days for results and lack...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $481,250 on April 1, 2026, to develop and test inhibitors of the reverse transsulfuration pathway as a novel treatment for Helicobacter pylori infection under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research evaluates aminooxyacetic acid (AOAA) and propargylglycine (PAG)—compounds initially developed to inhibit mammalian reverse transsulfuration pathway...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $274,991 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial membrane fusion sustains commensal resilience during enteric pathogen infection. The research examines molecular mechanisms by which commensal bacteria in the human gut withstand or recover from perturbations caused by enteric infections, particularly how Bacteroides...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $481,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 1, 2025, with a completion date of June 30, 2027. The grant supports research to develop high-throughput screening assays designed to identify inhibitors of lipoprotein synthesis in Helicobacter pylori, a gram-negative bacterium that colonizes...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas at Dallas $465,664 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of USENSE, an electrochemical point-of-care diagnostic platform for urinary tract infections. USENSE is a portable biosensor designed to quantitate three urinary analytes within 5–10 minutes and apply machine learning diagnostic algorithms to output UTI risk...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $195,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI201758). The recipient will develop a urea-inducible library of 217 transcription factors in Proteus mirabilis, a bacterium responsible for up to 44 percent of long-term catheter-associated urinary tract...